
|Articles|April 1, 2004
Role for rexinoids is expanding
Waikoloa, Hawaii - Rexinoids such as bexarotene have promise as an adjunct to other immune response modifiers in the treatment of patients with progressive cutaneous T-cell lymphoma (CTCL), according to Jacqueline M. Junkins-Hopkins, M.D. Such therapies are typically used in combination with interferon-alpha as well as with psoralen ultraviolet-A (PUVA) and extracorporeal photopheresis (ECP).
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Nearly Half of Female Psoriasis Patients Report IPV, Study Finds
3
New Analysis Finds Radiofrequency Microneedling Superior for Rosacea Erythema and Patient Satisfaction
4
Experts See Promise in AI for Atopic Dermatitis Care
5


















